XTLB (XTL Biopharmaceuticals Ltd) Net Profit

XTLB (XTL Biopharmaceuticals Ltd.) - company brandmark

A funding shortage is forcing XTL Biopharmaceuticals (XTLB) to cautiously acquire biopharmaceutical assets to strengthen its position. Environmental sustainability is confirmed by the implementation of ESG standards and the reduction of toxic waste. The company's net income demonstrates financial stability, where the current parameter equals 0.00. Business stability relies on the licensing of immunotherapeutic developments in the US and Israel to combat chronic pathologies.

XTLB (XTL Biopharmaceuticals) Net Profit history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company XTL Biopharmaceuticals Ltd. (XTLB)

- price and consensus price forecast:
Stock Quotes XTL Bio|XTLB - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization XTL Bio|XTLB - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share XTL Biopharmaceuticals|XTLB - Book Capitalization|Market Capitalization to Book Value xtlbio.com|XTLB - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio XTL Biopharmaceuticals|XTLB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio XTL Biopharmaceuticals Ltd|XTLB - Company Total Debt|Debts to Book Capitalization XTL Bio|XTLB - Company Long-Term Debt|Company Short-Term Indebtedness XTL Biopharmaceuticals|Immediate Liquidity xtlbio.com
- net income and valuation multiples indicators:
XTLB - Net Income
Summary company analysis:XTL Biopharmaceuticals
Core merchandise of XTL Biopharmaceuticals, Ltd.

Long-term patents for autoimmune disease therapies create a steady patient flow, providing XTL Biopharmaceuticals with a foundation for systematic revenue extraction. The company's profit volume dynamics reflect daily net income fluctuations driven by currency risks and raw material volatility, allowing investors to assess the amplitude of financial drawdowns and overall capital resilience through the analysis of this chart.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN: Net Income|PHAR (Pharming Corp) - Company Profit|NKTR (Nektar Therapeutics) - Net Income|UPB: Profit After Payment of Taxes|Company Net Income Zenas Biopharma|Company Net Income IMNM|Net Income GOSS (Gossamer Corp)|KALV (KalVista Corp) - Final Profit|Net Profit SEPN (Septerna Inc)|pieris.com - Company Net Income|Savara - Net Profit|Net Financial Result Rigel Pharma RIGL|AnaptysBio Corp (ANAB) - Company Net Income|Company Net Income Astria Corp (ATXS)|Company Net Income enGene Holdings Inc.|rapt.com - Profit After Tax|Net Profit JBIO|ACRS (Aclaris Therapeutics Inc.) - Final Profit|Net Profit KYTX (Kyverna)|Net Profit Tiziana Life Sciences, Ltd. TLSA|CABA - Company Net Income|Final Profit VTYX (ventyxbio.com)|Theratechnologies (THTX) - Company Net Income|Net Income Avalo Therapeutics, Inc.|ELDN (Eledon) - Net Profit|Net Profit Agenus, Inc|Net Profit CLYM|Net Income zurabio.com ZURA|Net Profit ATYR (aTyr Pharma)|Adagene Inc (ADAG) - Company Net Income|IMA: Net Income|STTK - Net Profit|EQ (equilliumbio.com) - Net Income|CNTB: Profit After Payment of Taxes|IMUX (Immunic Therapeutics) - Net Profit|Atara Biotherapeutics Inc (ATRA) - Net Financial Result|Net Profit IFRX|Net Income X4 Pharmaceuticals, Inc XFOR|Net Profit ACET (Adicet Bio, Inc.)|Net Profit Celularity Inc CELU|INMB - Company Net Income|BRNS: Company Net Income|Kezar Life Sciences, Inc (KZR) - Company Net Income|SABS - Net Financial Result|Net Income AKTX|Company Profit ENLV (Enlivex Therapeutics, Ltd.)|Net Income QTTB (Q32 Bio Inc.)|Profit After Payment of Taxes GOVX|Company Net Income Edesa EDSA|iBio Corporation - Company Net Income|Carisma Tx - Net Profit|BOLT: Company Net Income|hcwbiologics.com (HCWB) - Company Net Income|Profit After Tax APVO (Aptevo Therapeutics Inc.)|AIM (AIM ImmunoTech) - Net Profit|ADTX: Final Profit|Net Profit GRI|Net Profit xortx.com (XRTX)|Company Net Income Vyome Holdings HIND|Final Profit REVB|INDP - Company Net Income|BiondVax Pharmaceuticals (SCNI) - Net Income|CALI: Net Profit|Affimed N.V. (AFMD) - Net Profit|Net Income ALLK|HOOK: Final Profit|Net Profit IGMS|Net Financial Result iTeos Pharma|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP - Net Income|THRD - Company Net Income